Mohanty Salini, Feemster Kristen, Yu Kalvin C, Watts Janet A, Gupta Vikas
Center for Observational and Real World Evidence (CORE), Merck & Co, Inc, Rahway, New Jersey, USA.
Becton, Dickinson & Company, Franklin Lakes, New Jersey, USA.
Open Forum Infect Dis. 2023 Mar 7;10(3):ofad098. doi: 10.1093/ofid/ofad098. eCollection 2023 Mar.
Antimicrobial resistance (AMR) poses a significant challenge for treating pneumococcal disease. This study assessed AMR trends in from US children.
We evaluated antibiotic resistance, defined as facility antimicrobial susceptibility reports of intermediate/resistant, in 30-day nonduplicate isolates from children (<18 years of age) with invasive (blood or cerebrospinal fluid/neurological) or noninvasive (respiratory or ear/nose/throat) isolates at 219 US hospital inpatient/outpatient settings in the BD Insights Research Database (January 2011-February 2020). We used descriptive statistics to characterize the percentage of antimicrobial-resistant isolates and generalized estimating equations to assess variations in resistance over time.
Of 7605 isolates analyzed, 6641 (87.3%) were from noninvasive sources. Resistance rates were higher in noninvasive versus invasive isolates. Isolates showed high observed rates of resistance to ≥1 drug class (56.8%), ≥2 drug classes (30.7%), macrolides (39.9%), and penicillin (39.6%) and significant annual increases in resistance to ≥1 drug class (+0.9%), ≥2 drug classes (+1.8%), and macrolides (+5.0%).
Among US children over the last decade, isolates showed persistently high rates of resistance to antibiotics and significant increases in ≥1 drug class, ≥2 drug classes, and macrolide resistance rates. Efforts to address AMR in may require vaccines targeting resistant serotypes and antimicrobial stewardship efforts.
抗菌药物耐药性(AMR)对肺炎球菌疾病的治疗构成了重大挑战。本研究评估了美国儿童肺炎球菌的AMR趋势。
我们在BD Insights研究数据库(2011年1月至2020年2月)中,对美国219家医院住院/门诊机构中18岁以下患有侵袭性(血液或脑脊液/神经)或非侵袭性(呼吸道或耳/鼻/喉)感染的儿童的30天非重复肺炎球菌分离株进行评估,将抗生素耐药性定义为中介/耐药的机构抗菌药物敏感性报告。我们使用描述性统计来描述抗菌药物耐药分离株的百分比,并使用广义估计方程来评估耐药性随时间的变化。
在分析的7605株肺炎球菌分离株中,6641株(87.3%)来自非侵袭性来源。非侵袭性分离株的耐药率高于侵袭性分离株。分离株对≥1类药物(56.8%)、≥2类药物(30.7%)、大环内酯类(39.9%)和青霉素(39.6%)的耐药率较高,且对≥1类药物(+0.9%)、≥2类药物(+1.8%)和大环内酯类(+5.0%)的耐药性每年显著增加。
在过去十年中,美国儿童的肺炎球菌分离株对抗生素的耐药率持续居高不下,对≥1类药物、≥2类药物和大环内酯类药物的耐药率显著增加。应对肺炎球菌AMR的努力可能需要针对耐药血清型的疫苗和抗菌药物管理措施。